Search Results - chemotherapy%2ftargeted+therapy

3 Results

Sort By:

Induction of Synthetic Lethality with Epigenetic Therapy (ISLET) by Combined DNA Methyltransferase and Aurora Kinase Inhibition

Invention NoveltyThis invention is a novel paradigm for the induction of synthetic lethality through epigenetic modulations. This can induce functionality and efficacy of therapeutics against cancer cells that may have resistance to each therapeutic alone. Value PropositionThe complex and adaptive nature of the host of diseases termed cancer poses significant...

Published: 9/26/2024 | Inventor(s): Srinivasan Yegnasubramanian, William Nelson, Ajay Vaghasia, Philipp Nuhn

Keywords(s): Cancers, Chemotherapy/Targeted Therapy, Combination, Disease Indication, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities

DNA Polymerase Beta Inhibitors

INVENTION NOVELTYJohns Hopkins researchers have developed multiple unique inhibitors to DNA polymerase beta, a potential anti-cancer therapeutic target. VALUE PROPOSITIONThe DNA damaging agent temozolomide (TMZ) is used to treat melanoma and glioblastoma. TMZ damages cancer cell DNA by introducing single stranded breaks (SSBs). However TMZ’s efficacy...

Published: 9/26/2024 | Inventor(s): Marc Greenberg, Rakesh Paul

Keywords(s): Antagonists/Inhibitors, Cancers, Chemotherapy/Targeted Therapy, Combination, Disease Indication, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Rapid Induction of Cancer Cell Death by Synergistic Treatment of Tetra-O-methyl Nordihydroguaiaretic Acid (M4N) with either Rottlerin or Ly294002

Technical Details: M4N is an anti-cancer drug candidate, which is currently under the first phase of clinical trials. Although M4N can reduce tumor cell growth; it fails to induce quick tumor cell death. JHU scientists showed that the combination treatment of M4N with either two specific kinase inhibitors overcomes this problem. In vivo study demonstrated...

Published: 9/26/2024 | Inventor(s): Kotohiko Kimura, Ru Chih Huang

Keywords(s): Antagonists/Inhibitors, Cancers, Chemotherapy/Targeted Therapy, Combination, Disease Indication, Natural compounds, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type